Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

RIUMA. Repositorio Institucional de la Universidad de Málaga
Publication Artículo científico (JournalArticle)

Prenatal-lactational alcohol exposure induces sex-specific CX3CL1/CX3CR1 dysregulation linked to neuroendocrine imbalance and cardiovascular risk

  • Medina-Vera, Dina
  • García-Bao, Alba
  • Medrano, Mireia
  • Martín-Chaves, Laura
  • Rodríguez-Capitán, Jorge
  • Rodríguez de Fonseca, Fernando
  • Serrano, Antonia
  • Jiménez-Navarro, Manuel Francisco
  • Valverde, Olga
  • Pavón-Morón, Francisco Javier
Fetal alcohol spectrum disorder is associated with lasting neurodevelopmental and cardiovascular dysfunctions. The fractalkine axis CX3CL1/CX3CR1, a chemokine and its sole known receptor expressed in microglia and myeloid/endothelial cells, coordinates neuroimmune and vascular responses. We tested whether prenatal-lactational alcohol exposure (PLAE) is associated with sex-specific dysregulation of this axis along with integrated behavioral, neuroendocrine, inflammatory, and cardiovascular signatures. Pregnant C57BL/6 dams consumed 20% ethanol using a drinking-in-the-dark (DID) paradigm throughout gestation and lactation. Adult offspring (PND60–70) underwent behavioral testing (elevated plus maze and tail suspension test); plasma profiling of corticosterone, cytokines/chemokines, endothelial/coagulation markers, and matrix-remodeling enzymes; and cardiac transcriptional assays for stress- and inflammation-related genes (including Cx3cr1). Analyses were stratified by sex. PLAE females exhibited increased anxiety-like behavior, two-fold higher plasma CX3CL1, and upregulated cardiac Cx3cr1 compared with control females. PLAE males showed no behavioral or endocrine changes but evidence of matrix remodeling (elevated proMMP-9, reduced sP-Selectin). Across sexes, PLAE was associated with a proinflammatory/endothelial-activation profile (elevated IL13, IL18, and PAI-1, reduced CXCL16, higher proMMP-9) and altered cardiac expression of Nr3c2, Tnfrsf1a, Tlr4, and Nfkbia, compatible with early vascular risk. Independent of exposure, females exhibited reduced immobility and higher corticosterone, IL5, IL13, sE-Selectin, and thrombomodulin. Plasma CX3CL1 correlated inversely with exploratory and stress-coping behaviors, and positively with corticosterone, inflammatory/vascular markers, and cardiac Cx3cr1 and Tnfrsf1a. PLAE is associated with sex-specific dysregulation of the CX3CL1/CX3CR1 axis and convergent neuroimmune-vascular signatures indicative of subclinical endothelial dysfunction. These associative findings support the hypothesis that fractalkine-pathway modulation may mitigate long-term neurobehavioral and cardiovascular vulnerability after PLAE, warranting causal testing., Funding for open access charge: Universidad de Málaga / CBUA
RIUMA. Repositorio Institucional de la Universidad de Málaga
Publication Artículo científico (JournalArticle)

Early Oral Administration of D-Chiro-Inositol Reverses Hippocampal Insulin and Glutamate Signaling Deficits in the 3×Tg Humanized Mouse Model of Alzheimer's Disease

  • Pacheco-Sánchez, Beatriz
  • Verheul-Campos, Julia
  • Vargas, Antonio
  • Tovar, Rubén
  • Rodriguez-Pozo, Miguel
  • Navarro Juan, Antonio
  • Lopez-Gambero, Antonio
  • Baixeras, Elena
  • Serrano-Castro, Pedro
  • Suárez-Pérez, Juan
  • Sanjuan, Carlos
  • Rivera, Patricia
  • Rodriguez de Fonseca, Fernando
Background and Objective: Humanized models of Alzheimer’s disease (AD) provide valuable tools for investigating the mechanisms of this neurodegenerative disorder, the leading cause of dementia. These models enable the study of AD progression and the potential disease-modifying properties of drugs or dietary nutrients delivered through nutrition. Here, we examine molecular markers of metabolic and synaptic dysfunction in the hippocampus of 6-month-old 3×Tg-AD mice and assess whether a dietary insulin sensitizer can delay synaptic decline. Methods: First we characterized the molecular phenotype of 3×Tg-AD at 12 months using shotgun proteomics and phosphoproteomics to assess metabolic and synaptic changes in the hippocampus. Then, we characterized the effects of early daily oral D-chiro-inositol (DCI, Gyneos®) for three months, starting at 3 months of age, to test restoration of insulin signaling and glutamatergic synaptic markers. To this end we evaluated a) insulin signaling pathway components (insulin receptor, IRS1, PI3K, AKT, GSK3β) at mRNA, protein, and phosphorylation levels, and b) the expression of glutamate receptors (mGluR5, GluR1, GluR2, NMDAR1, NMDAR2A, NMDAR2B). Sex effects were explored. Results: 12-month 3×Tg-AD mice exhibit metabolic and synaptic dysfunction in the hippocampus, with phosphoproteomic changes suggesting altered glutamatergic synapses. At 6 months, disruptions in insulin signaling were evident, including altered expression and phosphorylation of insulin pathway components, and changes in glutamate receptor subunits. Early DCI treatment largely reversed these alterations. Several effects showed sex dependency. Conclusions: Early insulin-sensitizing intervention via DCI can restore insulin signaling and counteract hippocampal synaptic impairments in this AD model, supporting the potential for nutrient-based strategies to delay synaptic decline. Sex differences underscore the need to tailor therapeutic approaches in modifying AD progression., Instituto de Salud Carlos III (ISCIII), Ministerio de Ciencia e Innovación
RIUMA. Repositorio Institucional de la Universidad de Málaga
Publication Artículo científico (JournalArticle)

D-chiro-inositol modulates brain insulin-related signaling and reduces amyloid burden, neuroinflammation and cognitive decline in preclinical models of Alzheimer's disease

  • Pacheco-Sánchez, Beatriz
  • Lopez-Gambero, Antonio J.
  • Gavito, Ana L.
  • Rivera, Patricia
  • Suárez-Pérez, Juan
  • Sanjuan, Carlos
  • Nilsson, Per
  • Tambaro, Simon
  • Rodriguez de Fonseca, Fernando
Brain metabolic dysregulation and insulin-related signaling are increasingly recognized as contributing factors in Alzheimer's disease (AD) pathogenesis, disrupting amyloid-beta (Aβ) proteostasis and exacerbating neuroinflammation, and synaptic failure. However, current therapies yield inconsistent results due to a singular focus on specific targets, bioavailability and safety risks. D-chiro-inositol (DCI) is a natural compound with insulin-mimetic properties that has previously shown promising anti-inflammatory and neuroprotective results. This study investigated the neuroprotective efficacy of DCI using a tripartite approach: physiologically relevant primary neurons derived from AppNL-G-F knock-in mice, human hAPPswe SH-SY5Y cells, and the aggressive 5xFAD mouse model of AD. Toxicity, pharmacokinetic and pharmacodynamic profiling established DCI's safety and its ability to acutely improve systemic glucose handling. In vitro, DCI enhanced basal AKT and insulin receptor activation and modulated glycogen synthase kinase-3 beta (GSK-3β) activation, a kinase linked to amyloid precursor protein (APP) processing. This modulation was accompanied by reduced secretion of toxic Aβ42 species, preservation of neuronal integrity as determined by MAP2 immunostaining, and decreased overall APP protein levels. In vivo, chronic oral DCI administration significantly reduced hippocampal amyloid burden and promoted a shift in microglia from a reactive to a surveilling phenotype, with stronger effects in females. Notably, while DCI resolved microglial reactivity, astrogliosis remained largely unaffected, suggesting a cell-specific immunometabolic mechanism. These improvements translated into rescued recognition memory and normalized disinhibited risk-assessment behavior, indicative of restored hippocampal function. Collectively, DCI acts as a multi-modal agent by modulating insulin-related signaling, downregulating amyloid burden and attenuating neuroinflammation, making it an orally bioavailable candidate for AD therapy., Salud Carlos III (ISCIII), Spanish Ministry of Health, Spanish Ministry of Economy and Competitiveness
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Predictive performance for alcohol use disorder of polygenic scores based on the general addiction risk factor and problematic alcohol use

  • Pérez Gutiérrez, Ana M.
  • Flórez, Gerardo
  • Blanco, Vanessa
  • Vázquez, Fernando L.
  • Abellí, Enric
  • Ortega, Lluisa
  • Serrano, Antonia
  • Arias, Francisco
  • Navarrete, Francisco
  • Fonseca, Francina
  • Estévez, Valentín
  • Gómez Trigo, Jesús
  • Facal, Fernando
  • Arrojo, Manuel
  • Manzanares, Jorge
  • Muga, Roberto
  • Miquel, Laia
  • Rodríguez de Fonseca, Fernando
  • Torrens, Marta
  • Rubio, Gabriel
  • Costas, Javier
[Background] Polygenic scores (PGSs) may play a role in targeted prevention of alcohol use disorder (AUD) by risk stratification. A latent genetic factor representing common liability to different substance use disorders (SUDs), known as the addiction risk factor (AdRF), was recently characterized. Our aim was to analyze the predictive performance for AUD of the AdRF PGS, comparing it with PGSs of problematic alcohol use (PAU) and of a common liability factor to substance use involvement., [Methods] PGSs were estimated across two datasets, comprising 1637 treatment-seeking AUD patients and 4178 controls. Logistic regression was used to evaluate performance of ancestry-normalized PGSs. Subgroup sensitivity analyses were tested based on clinical data. Sex-dependent effects were assessed by comparing PGSs between sexes., [Results] Tail-based measures revealed a better performance of the AdRF PGS than the other PGSs. Compared with the remaining subjects, those at the top decile of PGS presented a 3.3-fold greater odds of AUD. Other analyses revealed similar performance of the AdRF and PAU PGSs. The effect estimates were larger in subgroups with addictive and psychiatric comorbidities, higher severity, and earlier age of onset. Women patients presented higher PAU and AdRF PGSs than men patients., [Conclusions] This new generation of PGSs is one step closer to precision public health for AUD prevention. Alcohol-specific genetic factors are not determinant for predicting AUD risk, which may benefit from shared genetic susceptibility among different SUDs. Our data suggest sex differences in genetic susceptibility, probably as a result of complex interplay between genes and social environment., This work was supported by grants 2014I075 and 2022I058 from Plan Nacional sobre Drogas (Ministerio de Ciencia, Innovación y Universidades), from the Support Groups de Recerca AGAUR-Gencat (2017 SGR 316, 2017 SGR 530); from Fondo de Investigación Sanitaria Instituto de Salud Carlos III (ISCIII) (PI22/00427; PI21/00488, PI16/00603 and PI20/00029); from Redes de Investigación Cooperativa Orientadas al Resultado en Salud (RICORS)-RIAPAD co-funded by ISCIII and the European Union (European Fund for Regional Development) (RD21/0009/0011, RD21/0009/0008, RD24/0003/0001, RD24/0003/0012 and RD24/0003/0016). The founders had no role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publications., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Cell-based regenerative interventions in Parkinson's disease: Overcoming pharmacological limitations

  • Padilla, Ana Lizeth
  • Lanciego, José Luis
  • Vila, Miquel
  • Castro Soubriet, Fernando de
  • Pozo, David
  • Rodríguez de Fonseca, Fernando
  • Serrano, Antonia
  • Sáez-Valero, Javier
  • Núñez, Lucía
  • Villalobos, Carlos
  • Tapias, Víctor
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic (DA) neurons and the pathological aggregation of α-synuclein. While current pharmacological therapies provide symptomatic relief, they do not halt or reverse disease progression. Cell-based regenerative strategies have emerged as promising approaches to restore DA function and target the complex, multifactorial pathophysiology of PD. This review critically examines current approaches, including transplantation of fetal ventral mesencephalic tissue, pluripotent stem cell-derived midbrain DA progenitors, and in vivo reprogramming of endogenous cells. In addition, supportive cell types, such as mesenchymal stromal cells and carotid body glomus cells, provide neuroprotective and immunomodulatory effects via paracrine signaling. We summarize preclinical and clinical evidence on graft survival, integration, and functional recovery, and discuss key determinants of therapeutic efficacy, including mitochondrial function and bioenergetic integrity, immune compatibility, and biomaterial scaffolding. Despite significant progress, major challenges remain regarding long-term efficacy, graft standardization, and host-graft interactions. Ongoing translational advances are poised to drive the development of disease-modifying cell therapies capable of delivering durable clinical benefits and improving long-term outcomes in PD., This work was supported by the Aligning Science Across Parkinson's (#ASAP-020505, USA) through the Michael J. Fox Foundation for Parkinson's Research (MJFF), Ministerio de Ciencia, Innovación y Universidades y Agencia Estatal de Investigación (MICIN/AEI, #PID2020-120308RB, Spain), CiberNed Intramural Collaborative Projects (#PI2020/09, Spain) and Fundación Mutua Madrileña de Investigación Médica (#FMM2020, Spain) to José L. Lanciego; Aligning Science Across Parkinson's (#ASAP-020505, USA) through the MJFF (USA), MICIN/AEI (#PID2020-116339RB-I00, Spain) to Miquel Vila; MICIN/AEI (#PID2022-143110OB-100, Spain), Fundación Ramón Areces (#CIVP19A5917, Spain), Fundación Merck Salud (2023, Spain) and Fundación Grupo de Afectados por Esclerosis Multiple (GAEM, #050601240006, Spain) in collaboration with research networks #RED2022-134081-T and #RED2022-134425-T to Fernando de Castro; MICIN/AEI (#PI22/00427 and #PI20/01399, Spain) and European Regional Development Funds-European Union (ERDF-EU) to Fernando Rodríguez de Fonseca and Antonia Serrano; MICIN/AEI (#RTI2018-098432-BI00), Junta de Andalucía (#PI-232-2022 and #CTS-677), Fundació Catalana d’ELA Miquel Valls (2022, Spain), Fundación Juntos contra la ELA (2023, Spain) to David Pozo; Fondo de Investigaciones Sanitarias (#PI22/01329, Spain), Fondo Europeo de Desarrollo Regional (FEDER), and Dirección General de Ciencia e Investigación de la Generalitat Valenciana (CIAICO/2024/313, Spain) to Javier Sáez-Valero; Excellence Program from Junta de Castilla y León (#CCVC8485, Spain) and MICIN/AEI (#PID2021-125909OB-100, Spain) to Carlos Villalobos and Lucía Núñez, and Junta de Castilla y León (#VA294P18, Spain) to Lucía Núñez; María Zambrano's Excellence Program from the MICIN/AEI (#CONVREC-2021-278, Spain), University of Valladolid and the Internationalization program of Junta de Castilla y León (#CL-EI-2021-09, Spain) to Victor Tapias., Peer reviewed